BOSTON, Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of the first milestone of ...

Earnings Call Insights: Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2025 Jason Kelly, Founder, CEO & Director, emphasized Ginkgo’s mission to "make biology easier to engineer" and outlined three major ...

Ginkgo Bioworks Holdings, Inc. ( (DNA)) has released its Q3 earnings. Here is a breakdown of the information Ginkgo Bioworks Holdings, Inc. presented to its investors. Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks reported solid Q3 results, but underlying performance was weaker than the financials suggest after accounting for meaningless non-cash revenue. Ginkgo's new business model focuses on ...

AI-driven autonomous robots are coming to biology laboratories, but researchers insist that human skills remain essential.

Good evening. I'm Joseph Fridman, Director of Communications and Corporate Affairs here at Ginkgo, where it's my fifth year. During that time, I've had the pleasure and the privilege of working with ...

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It ...

In the latest close session, Ginkgo Bioworks Holdings, Inc. (DNA) was down 5.92% at $8.27. This move lagged the S&P 500's daily loss of 0.51%. Elsewhere, the Dow saw an upswing of 0.53%, while the ...